This morning, Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for generalised anxiety disorder (GAD). It comes just two months after it posted positive topline results from its first Phase 3 program in major depressive disorder (MDD), Emerge, making it a successful summer for the LSD developer…
